

Chapter 5

Anticholinergic Drug

- 1- Antimuscarinic Drug
(Parasympatholytics)
- ↓ (muscarinic agonist)
- ① Atropine
 - ② Scopolamine
 - ③ Buscopan
 - ④ Homatropine
 - ⑤ Tropicamide
 - ⑥ Ipratropium
 - ⑦ Oxybutynin

2- Antinicotinic Drug

- ↓
- 1- Ganglion blocker
 - 2- NMJ blocker

Cholinergic agonist *
Parasympathetic, i.e. Ach, i.e. done

Cholinergic antagonist *
Ach, i.e. done

① Antimuscarinic agent

1. Atropine → tertiary belladonna alkaloid CNS not
- Act centrally and peripherally
 - action 4 hours (except topical to the eye 7-14 days)

action → eye → mydriasis, cycloplegia (inability to focus for near vision)
↑ intraocular pressure, ↑ closure angle glaucoma

GI → antispasmodic, reduced gastric motility
without affect ~~gastric~~ HCl acid production
↓ saliva ↓ urination

Cardiovascular → 1- Low dose → M_1 inhibitory to
presynaptic neuron cause increase Ach
secretion (decrease heart rate)

2- High dose → ~~M_2~~ blocking M_2 (SA)
Cause (increase heart rate)

Secretion → dryness of the mouth (xerostomia)

atropine Therapeutic use

- 1- Ophthalmic → Topical to eye for measurement of refractive error
دول في العينين تستخدم tropicamide cyclopentolate - 1 drop
(6h) (24h)
- 2- antispasmodic
- 3- Antisecretory (block secretion of upper and lower respiratory tract prior surgery)
- 4- treat bradycardia
- 5- Antidote for (organophosphate, physostigmine, mushroom poisoning)

Atropine Adverse effect

- 1- blurred vision "sandy eye"
- 2- Constipation
- 3- urinary retention
- 4- tachycardia
- 5- dangerous in children causes increase in body temperature

2 Scopolamine → - CNS ^{سج}
- side effects ^{آثار جانبية}
atropine

- most effective anti-motion sickness drug
- blocking short-term memory
- produce sedation, ~~excitement~~ euphoria

جسك ^{جسك} - prevent motion sickness may available as topical patch last for (3 days) active.
- prevent post operative nausea and vomiting

3 ipratonium → SAMA → acute management of asthma + COPD

Atiotropium → LAMA → chronic management of asthma + COPD

glycopyrrolate → LAMA → COPD

Acridinium → LAMA → COPD

4 cyclopentolate & tropicamide → mydriasis & cycloplegia
(24h) (6h)

[illegible]

Oxybutinin
Darifenacin
Solifenacin
Tropium
Fesoterodine
Tolterodine

- overactive bladder & urinary incontinence
- bind competitively blocking (M₃) receptor in bladder
- ↓ intravesical pressure
- ↓ frequency of bladder contraction
- ↑ bladder capacity
- metabolized by CYP450 except tamsulosin
- once daily, oral dosage

① Darifenacin, solifenacin → selective M₃ adverse effect
 کم خون قلیہ و دل

(2) Oxybutinin → neurogenic bladder, its present topical gel, transdermal patch, oral

(3) *trospium* → هذا نبات غشائي

- metabolized by ester Hydrolysis

عہدہ کاش کاش

- treat overactive bladder in patient with dementia

يعالج المسألة السلطة بحالة التي مداهم
خبرك لأن يعني لا CNS بشكل قليل


Ganglionic blockers

- act on nicotinic receptor of
 - ① Parasympathetic autonomic ganglia
 - ② Sympathetic autonomic ganglia
 - ② block ion channels of the autonomic ganglia
 - ③ show no selectivity toward the parasympathetic or sympathetic ganglia, not effective as neuromuscular antagonists
- * Rarely used Therapeutically, but serve as a tool in experimental pharmacology

- Nicotine & (ganglionic blocker)

- * Component of cigarette smoke, no therapeutic benefit, deleterious to health
- * nicotine depolarize autonomic ganglia resulting first in stimulation and then paralysis in all ganglia
- * Stimulatory effect cause increase release of neurotransmitter
 - ACh → increase peristalsis and secretion
 - NE → ↑ BP, ↑ cardiac output
- * Nicotine at higher Dose causes fall in blood pressure due to ganglionic blockade.

Non depolarizing Competitive blockers



blocks cholinergic transmission between motor nerve ending and nicotinic receptor on the skeletal muscle

NON Depolarizing (Competitive) blocker

- 1- Cistatracurium → eliminate by (Hofmann elimination) renally excreted (renal and hepatic dysfunction) ^{من الكلى}
- 2- mivacurium → plasma cholinesterase elimination
- 3- pancuronium → eliminated in urine
- 4- rocuronium → eliminated in bile
- 5- Vecuronium

action

* AT Low Dose → - block Ach at nicotinic receptor
 - it can overcome the block by use of cholinesterase inhibitor (edrophonium, physostigmine, Neostigmine)
~~response~~ - The muscle respond to direct electrical stimulation from a peripheral nerve stimulator

* AT high Dose → - block the ion channel of The motor endplate
 - reducing The ability of cholinesterase inhibitor to reverse The action of Neuromuscular block
 - muscle doesn't respond to The electrical stimulation

* Action → ~~paralyze~~ Contracting muscles:

First muscle recover ^{أول العضلات التي تستعيد}
 1) Face and eye 2) Fingers, Limbs, neck
 3) intercostal muscle 4) diaphragm

(PK) - IM or IV
 - ~~paralyze~~ don't cross BBB

* Drug interaction → 1- cholinesterase inhibitor → ^{يُضيق القناة الأيونية}
 2- Hydrogenated Hydrocarbon anesthetic (desulfurane) ^{يُضيق القناة الأيونية}
 3- Aminoglycoside antibiotic (gentamicin, tobramycin)
 4- Calcium channel blocker

neuro-muscular blocker
 * Succinylcholine → Vecuronium ^{يُضيق القناة الأيونية}

15/5/1

Depolarizing agent (succinylcholine)

- Depolarizing the plasma membrane of the muscle fiber, similar to Ach.
- Succinylcholine attach to nicotinic receptor.

Action

Phase I: depolarizing agent cause opening of sodium channel result in depolarization of the receptor.

Phase II: Continuous Depolarization gives way to gradual repolarization as the sodium channel closes or is blocked, this cause flaccid paralysis.

respiratory muscle are paralyzed Last

- Succinylcholine hydrolyzed by plasma pseudocholinesterase.

Therapeutic use

- 1- useful when rapid endotracheal intubation is required during the induction of anesthesia
- 2- ~~used~~ used during electroconvulsive shock treatment

Adverse effect

